Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 Supported in part by University of Colorado Shared Resources ...

First-line nivolumab plus ipilimumab significantly improved survival versus lenvatinib or sorafenib in patients with unresectable liver cancer. The median overall survival of 23.7 months with the ...

Pre-specified thresholds for statistical significance were not met. Nivolumab plus ipilimumab did not improve overall survival (OS) when compared to chemotherapy in a phase 3 trial of patients with ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant combination immunotherapy regimens produced higher pathologic response rates than monotherapy in a ...

A Prescription Drug User Fee Act target date of June 23, 2025 has been set for the application. The sBLA is supported by data from the randomized, open-label phase 3 CheckMate 8HW trial ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

Please provide your email address to receive an email when new articles are posted on . Nivolumab significantly improved RFS for advanced melanoma compared with ipilimumab after 9 years of follow-up.

A lower dose of an immunotherapy drug might help patients better fight melanoma A 'flipped' dose of an immunotherapy cocktail of nivolumab/ipilimumab provided better results with fewer side effects ...